Detalhe da pesquisa
1.
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
N Engl J Med
; 388(6): 511-517, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780675
2.
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
N Engl J Med
; 387(16): 1445-1455, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260792
3.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Lancet
; 402(10412): 1541-1551, 2023 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738999
4.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891380
5.
Trial of Spesolimab for Generalized Pustular Psoriasis.
N Engl J Med
; 385(26): 2431-2440, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34936739
6.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
N Engl J Med
; 385(24): 2219-2229, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34879448
7.
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3â years of treatment in randomized phase III trials.
Br J Dermatol
; 190(4): 477-485, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950894
8.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226713
9.
Nail psoriasis and nail lichen planus: Updates on diagnosis and management.
J Am Acad Dermatol
; 90(3): 585-596, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38007038
10.
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
J Am Acad Dermatol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447700
11.
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
J Am Acad Dermatol
; 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588819
12.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
J Am Acad Dermatol
; 90(4): 775-782, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38122848
13.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
J Am Acad Dermatol
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556093
14.
Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.
J Am Acad Dermatol
; 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38331098
15.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451052
16.
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis.
J Eur Acad Dermatol Venereol
; 2024 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38334243
17.
Post-Hyaluronic Acid Filler Reaction Treated With Abrocitinib: A Case Report.
J Drugs Dermatol
; 23(1): 1355-1356, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38206137
18.
Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK).
J Drugs Dermatol
; 23(5): 338-346, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38709702
19.
Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis.
J Allergy Clin Immunol
; 152(4): 927-932, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37453613
20.
Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis.
J Allergy Clin Immunol
; 152(4): 916-926, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37453614